Codexis Inc
Chiusa
SettoreSettore sanitario
2.56 4.07
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
2.5300000000000002
Massimo
2.63
Entrata | -18M -8.7M |
|---|---|
Vendite | -24M 15M |
EPS | -0.1 |
Margine di Profitto | -57.083 |
Dipendenti | 146 |
EBITDA | -23M -6.4M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +168.48% upside |
Utili prossimi | 12 ago 2026 |
|---|
Capitalizzazione di Mercato | -1.8M 226M |
|---|---|
Apertura precedente | -1.51 |
Chiusura precedente | 2.56 |
Notizie sul Sentiment di mercato
By Acuity
50%
50%
118 / 342 Classifica in Healthcare
Codexis Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Codexis Inc
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
